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ABSTRACT
Objective: To evaluate the analgesic activity of ibuprofen against paracetamol using a simple
pain model.
Design: A double-blind study.
Setting: Twenty general practitioners in Harare, Zimbabwe.
Patients: Adults with acute sore throat of a maximum of two days’ duration.
Interventions: One hundred and thirteen patients with acute pain associated with tonsillo-
pharyngitis randomly received either 400mg ibuprofen or 1000mg paracetamol. The study
design included repeated administration up to 48 hours to assess tolerability.
Main outcome measures: At hourly intervals for six hours after the first dose of treatment,
the patients evaluated pain intensity on swallowing, difficulty in swallowing and global pain
relief according to visual analogue scales.
Results: Ibuprofen 400mg was significantly more effective than paracetamol 1000mg in all
three ratings, at all time-points for pain intensity and difficulty in swallowing, and from two
hours onwards for pain relief. There were no serious adverse effects and no statistically
significant difference in the incidence of adverse effects in the two treatment groups.
Conclusions: Sore throat pain provided a sensitive model to assess the analgesic efficacy of
class I analgesics and discriminated between the analgesic efficacy of ibuprofen and
paracetamol.
INTRODUCTION
Various clinical conditions have been used as models
to assess pain relief following the administration of different
analgesics. These models include dental pain,
dysmenorrhoea, osteoarthritis of the knee and, more
recently, sore throat pain. Sore throat, associated with
tonsillitis, is a frequent complaint, and has been shown to
provide a sensitive model for the evaluation of class I
analgesics(1,2). In these studies patients’ descriptions of
their pain were highly correlated with the physicians’
assessments of the severity of sore throat. The sore throat
model has been successfully employed in clinical trials to
distinguish between different analgesic agents and placebo,
and between different doses of an analgesic(4).
The sore throat model consisted of five subscales:
pain intensity, relief of pain, change in pain, pain severity
description (mild, moderate and severe), and maximum
reduction in pain (no reduction to complete reduction).
The scales also included two sensory qualities of sore
throat pain (swollen throat and difficulty in swallowing)
and the assessment period was set at six hours postdose
allowing patients to complete the assessments between
three to six  hours at home. Furthermore the addition of a
pain subscale (a 200mm visual analogue scale(VAS)) was
added to discriminate between the analgesic effects of
aspirin and an aspirin/caffeine combination.
Two extensively used analgesics in the treatment of
sore throat pain are ibuprofen and paracetamol. Despite
their wide use, to our knowledge there are no studies that
have compared their relative analgesic efficacy using a
sore throat model.
The present randomised, double-blind, multicentre,
parallel group comparative study was performed to validate
the sore throat model described.
MATERIALS AND METHODS
Study participants: In this twenty GP practice, primary care
study, adults consulting their general practitioner with acute sore
throat (onset within two days) were recruited into the study.
Patients were eligible to enter the study if they had at least
moderately severe throat pain (a score greater than 50mm on a
100 mm VAS with end-points no pain and very intense pain)
associated with an obvious diagnosis of tonsillo-pharyngitis (a
score of 4 or more on the 10-point tonsillo-pharyngitis scale).
Patients excluded from the study were: those who had a
history of hypersensitivity to ibuprofen, aspirin, paracetamol or
any other NSAID or any contraindication to treatments; those
who had used any local treatment such as an anaesthetic spray
within two hours, any analgesic treatment within six hours and/
or any anti-inflammatory treatment within three days prior to the
initial consultation; those who had mouth breathing as a result of
severe nasal congestion (mouth breathing could alter the
symptomatology and natural history of acute sore throat thus
confounding the results).
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Patients should not have received any antibiotic treatment
within the week prior to the initial consultation. However,
patients could be treated with antibiotics, provided that this
medication was not started until at least six hours after the first
dose of study treatment. All patients provided written consent
before participating in the study.
Study assessments: The severity of sore throat was assessed
by the patient, using the following three indices: pain on
swallowing according to a continuous 100 mm visual analogue
scale (VAS) with end-points of no pain to very intense pain;
relief of sore throat pain using a numeric scale (end-points 0%
relief to 100% relief; in blocks of 10%) and; difficulty in
swallowing using a VAS of 100 mm (end-points of no difficulty
to very great difficulty).
These assessments were made at home by the patient every
hour for six hours following the first dose of treatment. In
addition, a global evaluation of treatment efficacy was made
after 48 hours at the end of the study by the patients according to
4-point verbal scales (not satisfied, a little satisfied, mostly
satisfied, very satisfied).
The severity of sore throat was also assessed by the
investigator at both the screening and final visits, using the
tonsillo-pharyngitis score, an index that takes into account as a
sum of ratings (on a 0 to 2-point scale) the intensity of each of five
clinical features of tonsillo-pharyngitis (oral temperature,
oropharyngeal coloration, oropharyngeal erythaema, cervical
adenopathy and cervical adenitis). A global evaluation of
treatment efficacy was also performed at the end of the study by
investigators according to 4-point verbal scales (none, moderate,
good, very good). All adverse effects during the study period
were collected.
Study treatments: Patients meeting admission criteria were
allocated by a computer-generated randomisation code to receive
either 400mg ibuprofen or 1000 mg paracetamol under double-
blind conditions. To maintain blinding, a double-dummy design
was used. All treatments were supplied by Knoll, UK. Each
treatment dose comprised either one tablet of ibuprofen 400mg
and two capsules of paracetamol placebo or one tablet of ibuprofen
placebo and two capsules of paracetamol 500mg. Treatment was
to be taken three times daily for up to two days with a minimum
of six hours between each dose.
Study design: The first dose of study treatment was
administered in the GP’s office, after which patients were
discharged. Patients evaluated their throat pain every hour over
the next six hours, during which time they were to take no further
doses of study medication or use any other treatment. If antibiotic
therapy was considered necessary, this was only to be started
after six hours following the first dose of analgesic. Patients
recorded the results of their hourly assessments on a diary card.
This card was also used to record the times of subsequent
treatment doses, as well as the occurrence of any adverse effects,
over the rest of the study period (two days).
Patients returned for a final consultation after 48 hours, at
which time tonsillo-pharyngitis scores and global assessments of
efficacy were recorded.
Statistical methods: Observed differences between the two
treatment groups in pain or swallowing were tested for significance
(p < 0.05) using a 2-factor analysis of variance (ANOVA) with
centre and treatment as main fixed effects.
The evolution of pain on swallowing was analysed as the
absolute difference from baseline (pain intensity difference -
PID), both over one hour (h) one to six hours using a 2-factor
ANOVA with repeated measures and at individual time-points
using a 2-factor ANOVA. The sum of pain intensity differences
at six hours (SPID) was analysed using a 2-factor ANOVA. The
difficulty in swallowing and global relief scales were analysed
similarly as the absolute difference from baseline (1h to 6h) and
at each time-point, and as the sum of the difference scores at 6
hours (analogous to PID and SPID), but using a 1-factor ANOVA
in all cases.
If patients took any medication within the first six hours,
pain assessments after treatment intake were replaced with the
score at the time of re-medication using the last observation-
carried-forward method. Time to re-medication, the final tonsillo-
pharyngitis score and the global evaluation of treatment efficacy
were compared between groups using a Wilcoxon test.
The evolution of pain on swallowing was considered as the
primary efficacy variable in this study and intent-to-treat analyses
were supported by analyses using a per-protocol population.
The tolerability analyses were carried out on all patients
who took at least one dose of study medication. The number of
patients who experienced at least one adverse effect during the
study was compared between groups using a Chi2 test.
RESULTS
Study population: Fifty seven patients were randomly
assigned to the ibuprofen treatment group and 56 to the
paracetamol group. All 113 patients took at least one dose
of study medication and 110 patients (55 in each group)
completed the study.
Nine patients had major deviations from the protocol
during the study that necessitated their exclusion from the
per-protocol analysis of the primary efficacy variable.
Seven patients were treated with antibiotic medication
within three hours of the first dose of study treatment, one
patient in the ibuprofen group took paracetamol at days 0
and one of the study, and one patient had pain assessment
times that deviated by more than 30 minutes from the
protocol-defined schedule. The per-protocol population
thus contained 104 patients (52 in each group). There were
no significant differences between the two groups at
baseline assessment, particularly in the pertinent clinical
features (Table 1).
Table 1
Clinical features of the study population with tonsillopharyngitis at
day 0
Feature (mean ± SD) Treatment group
Ibuprofen 400 mg Paracetamol
 (n=57) (1000 mg)
n=56
Age 37.5 (19-58) 37.6 (20-61)
Gender: Males 28 (49) 23 (41)
Duration of sore throat 1.1±0.48 1.1±0.56
Tonsillopharyngitis
score (10) 6.4±1.2 6.4±1.1
Pain intensity on
 swallowing (mm) 76.6±14.3 73.3±11.5
Difficulty in swallowing (mm) 73.9±14.3 71.8±14.6
All between group differences were non-significant (p>0.1)
Efficacy: The sore throat model used in this study
discriminated between the analgesic efficacy of 400mg
ibuprofen and 1000 mg paracetamol. Ibuprofen was
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Table 2
Absolute changes from baseline (mean±SD) in pain measures at each hour over the first six hours after the first treatment
Time (h) Pain on swallowing (mm) PID Difficulty in swallowing (mm) PID
Ibuprofen Paracetamol P value (A) Ibuprofen Paracetamol
1 -12.5±16.2    -4.2±8.0 <0.001 -11.8±14.9    -5.1±9.8
2 -22.5±14.3 -10.9±14.3 <0.001 -21.5±20.0 -12.4±15.1
3 -29.2±19.4 -15.5±14.3 <0.001 -28.8±21.1 -17.0±15.9
4 -30.0±19.3 -17.3±15.2 <0.001 -29.2±20.2 -18.5±17.4
5 -28.9±20.5 -15.2±12.6 <0.001 -27.8±21.1 -16.3±16.4
6 -28.8±22.1 -14.0±14.3 <0.001 -28.0±22.7 -15.4±18.5
(a)  Two factor ANOVA NS=non-significant
(b)   One factor ANOVA PID=Pain intensity difference
significantly superior to paracetamol in all three pain
measurement scales used.
Ibuprofen resulted in statistically significantly greater
reductions in the intensity of pain on swallowing (the
primary efficacy variable) at each time-point over the six
hour evaluation period (Table 2), as well as a statistically
significant difference in the overall effect, that is, the sum
of changes from baseline to 6 hours postdose (Table 3).
Ibuprofen reduced the difficulty in swallowing at
each time-point over the six-hour evaluation period
significantly more than paracetamol (Table 2). Overall
effect, that is, the sum of reductions in the difficulty in
swallowing from baseline to six hours postdose, was
significantly greater with ibuprofen (Table 3). Ibuprofen
was significantly superior to paracetamol in the
improvement in pain relief at time-points h2 to h6 (Table
2) as well as in the overall effect (Table 3).
There were no significant differences between
treatment groups in the time to re-medication or in the
improvement in tonsillo-pharyngitis score at the end of the
study. The median time for remedication in both groups
was 360 minutes, with paracetamol showing a wider
variation.
Table 3
Sum values of changes in pain measures over the first six hours after
treatment
Treatment group
Variable Ibuprofen Paracetamol p value
(n=57) (n=56)
Pain on swallowing
 (SPID) -151.7±102.2 -77.1±68.0 <0.001 (a)
Difficulty in swallowing -147.2±106.0 -84.6±82.6 <0.001 (b)
Pain relief +215.1±130.5 +154.5±101.7 0.007 (b)
(a) Two factor ANOVA
(b) One factor ANOVA
SPID=sum of pain intensity differences
Table 4
Adverse effects reported during the study (a)
Treatment group
Ibuprofen 400 mg Paracetamol 1000 mg
(n=57) (n=56)
Patient with at least  one
adverse effect (No (%)) 12 (21.1) 11 (19.6)
Total number of effects 17 15
Diarrhoea 2 1
Oesophagitis 1 –













(a) Between group comparison of patients with at least one adverse effect
was non-significant (p=0.85)
Tolerability: Twelve (21%) patients in the ibuprofen
group and eleven (20%) patients in the paracetamol group
experienced at least one adverse effect (p = 0.85). Most
adverse effects with ibuprofen were gastrointestinal
disturbances (Table 4), but were all of mild/moderate
intensity and did not lead to discontinuation of study
treatment, except for one case of severe gastralgia in the
ibuprofen group, which was not associated with serious
gastrointestinal complications. The most frequent adverse
effects with paracetamol were rhinitis, headache and cough.
DISCUSSION
This clinical study provides substantiation that the
sore throat pain model is a sensitive assay of analgesic
activity and confirms the superiority of ibuprofen over
paracetamol.
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Sore throat pain appears to be a valid model for
nociceptive pain with a demonstrated ability to discriminate
the oral analgesics aspirin, paracetamol and ibuprofen
from placebo. Like dental pain models(5, 6), this model
enables significant analgesic effects to be demonstrated
using relatively small sample sizes. The model also appears
able to discriminate between different active agents, and
thus fulfils scientific criteria for an acceptable pain
model(1).
Our study highlighted the clinically relevant
differences in analgesic efficacy between a single dose of
ibuprofen 400mg and paracetamol 1000mg. Differences
between the treatments were assessed using three pain
measures: intensity of pain on swallowing, “difficulty in
swallowing’, a frequent complaint correlating highly with
pain intensity and serving as a sensitive indicator of
pharmacological response and; an assessment of relief of
pain using a 10-block numerical scale
Upside assay sensitivity was highlighted by comparing
the PID scores for all three measures between ibuprofen
400mg and paracetamol 1000 mg at each hour over the six
hours immediately following the first dose of treatment.
Statistically significant differences between treatments
were detected from as early as one hour following treatment
for pain intensity and dysphagia, and from two hours
onwards for pain relief. The various subjective assessments
of characteristics of pain (dysphagia) and pain relief thus
demonstrated analgesic discrimination and yielded
consistent statistically significant results that agreed with
the result obtained using the conventional pain intensity
scale.
Although the study was randomised and carried out in
accordance with good clinical practice, it had some
limitations, which included: primary assessment of efficacy
only after the first dose; involvement of many GP practices
which have confounded the outcome of the treatment
although no statistical interactions between treatment and
centres were detected; and the severity of the disease was
at least moderate. These factors may, in certain
circumstances, affect the generalisability of the study
results.
The differences between treatments were both
statistically and clinically significant. Ibuprofen provided
at least ten per cent more pain relief than paracetamol as
measured by the VAS. This study has also shown that all
assessments can be made at home by the patients. This
makes the model appropriate for assessing the analgesic
activity of over-the-counter medications.
Practising physicians should consider ibuprofen as an
effective alternative to paracetamol in the treatment of
sore throat pain. The superiority of ibuprofen in the
treatment of sore throat pain may be due to its superior
inhibition of peripheral prostaglandins. At elevated doses
(more than 1200mg per day), ibuprofen is known to have
anti-inflammatory activity. However, the evidence of this
anti-inflammatory activity at lower doses is questionable.
The sore throat model should be considered by researchers
as a sensitive assay in measuring analgesic and potentially
anti-inflammatory activities of medications.
In conclusion, this study confirmed that the sore
throat model is a sensitive assay in measuring relative
analgesic efficacy of commonly used medications.
Ibuprofen provided very rapid relief of painful symptoms
with a significant advantage over paracetamol from as
early as just one hour following a single dose of treatment.
Both treatments were well tolerated and any adverse
effects were generally mild or moderate and did not
require discontinuation of therapy.
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